Boehringer Ingelheim has reported that its experimental therapy, spesolimab, substantially improved signs and symptoms of flare in individuals with generalised pustular psoriasis (GPP) in Phase II Effisayil 1 clinical trial.
A humanised, selective antibody, spesolimab hinders interleukin-36 receptor (IL-36R) activation.
IL-36R is a signalling pathway within the immune system associated with various autoimmune ailment pathogeneses, such as GPP.
The 12-week trial enrolled 53 subjects with a GPP flare, who were randomised into a 2:1 ratio to receive one 900mg spesolimab intravenously or placebo.
A GPP Physician Global Assessment (GPPGA) pustulation subscore of 0 indicating no visible pustules at the first week was the trial’s primary goal.
The GPPGA score of 0/1 signifying clear/almost clear skin at week one was the key secondary goal of the trial.
Findings showed that 54% of subjects in the spesolimab arm had no visible pustules versus 6% in the placebo arm, meeting the primary endpoint.
Furthermore, 43% of subjects who received spesolimab termed had clear/almost clear skin as against 11% of subjects treated with placebo.
Continued pustular and skin clearance were observed during the course of the trial with clinically significant enhancement in quality of life and symptoms including pain and fatigue reported in the treatment arm versus placebo.
Boehringer Ingelheim Dermatology Clinical Development and Medical Affairs head Dr Emmanuelle Clerisme-Beaty said: “At Boehringer Ingelheim, we are committed to finding transformative therapies to help advance treatment for people who urgently need them.
“The findings indicate that spesolimab may have a significant and positive impact on patients experiencing a GPP flare.”
A neutrophilic skin condition, GPP is caused by the build-up of neutrophils in the skin, leading to painful, sterile pustules in the body.
In September this year, Boehringer Ingelheim and Amgen have entered a clinical Phase I collaboration to evaluate a potential combination therapy for cancer.